Related references
Note: Only part of the references are listed.Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies
Gautam Borthakur et al.
HAEMATOLOGICA (2013)
Gene mutations of acute myeloid leukemia in the genome era
Tomoki Naoe et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2013)
Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial
A. K. Burnett et al.
LEUKEMIA (2013)
AKT Signaling as a Novel Factor Associated with In Vitro Resistance of Human AML to Gemtuzumab Ozogamicin
David B. Rosen et al.
PLOS ONE (2013)
Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004
Henrik Hasle et al.
BLOOD (2012)
AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia
Todd M. Cooper et al.
CANCER (2012)
Clinical studies of acute myeloid leukemia in the Japan Adult Leukemia Study Group
Shuichi Miyawaki
INTERNATIONAL JOURNAL OF HEMATOLOGY (2012)
Molecular markers in acute myeloid leukaemia
Andrea Kuehnl et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2012)
Remission induction in acute myeloid leukemia
Eytan M. Stein et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2012)
Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia
Alan K. Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
Sylvie Castaigne et al.
LANCET (2012)
Importance of inducible multidrug resistance 1 expression in HL-60 cells resistant to gemtuzumab ozogamicin
Taichi Matsumoto et al.
LEUKEMIA & LYMPHOMA (2012)
Flow cytometric analysis of de novo acute lymphoblastic leukemia in childhood: report from the Japanese Pediatric Leukemia/Lymphoma Study Group
Shotaro Iwamoto et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2011)
Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial
Alan K. Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902
Richard M. Stone et al.
LEUKEMIA RESEARCH (2011)
Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study
Christian M. Zwaan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Multidrug transporter proteins and cellular factors involved in free and mAb linked calicheamicin-γ1 (gentuzumab ozogamicin, GO) resistance and in the selection of GO resistant variants of the HL60 AML cell line
Maurizio Cianfriglia et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2010)
Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial
Jeffrey E. Rubnitz et al.
LANCET ONCOLOGY (2010)
CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma
Akihiro Takeshita et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Deficient activation of Bak and Bax confers resistance to gemtuzumab ozogamicin-induced apoptotic cell death in AML
Petra Haag et al.
EXPERIMENTAL HEMATOLOGY (2009)
Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study
Yukio Kobayashi et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2009)
Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin
Farhad Ravandi et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells
A. Takeshita et al.
LEUKEMIA (2009)
Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: A report from the children's oncology group
Richard Aplenc et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Gemtuzumab ozogamicin, citosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myelold leukemia
L. Fianchi et al.
ANNALS OF ONCOLOGY (2008)
Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia
Ahmed Aribi et al.
CANCER (2007)
The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells
B. ten Cate et al.
LEUKEMIA (2007)
Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia
Massimo Breccia et al.
HAEMATOLOGICA (2007)
High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group
A-L Taksin et al.
LEUKEMIA (2007)
A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse
Joseph Moore et al.
LEUKEMIA RESEARCH (2006)
Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia
E Estey et al.
BLOOD (2006)
A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing
T Hernandez-Caselles et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2006)
Two patients with all-trans retinoic acid-resistant acute promyelocytic leukemia treated successfully with gemtuzumab ozogamicin as a single agent
A Takeshita et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2005)
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence
RA Larson et al.
CANCER (2005)
Gemtuzumab ozogamicin (Mylotarg®) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia:: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups
S Amadori et al.
LEUKEMIA (2005)
Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukemia
P Chevallier et al.
LEUKEMIA RESEARCH (2005)
Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia
RJ Arceci et al.
BLOOD (2005)
Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells
A Takeshita et al.
LEUKEMIA (2005)
Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity
RB Walter et al.
BLOOD (2005)
CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance
ML Linenberger
LEUKEMIA (2005)
Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity
I Jedema et al.
LEUKEMIA (2004)
First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients
PP Piccaluga et al.
LEUKEMIA RESEARCH (2004)
The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin
RB Walter et al.
BLOOD (2004)
Gemtuzumab ozogamicin (Mylotarg (R)) in children with refractory or relapsed acute myeloid leukemia
D Reinhardt et al.
ONKOLOGIE (2004)
High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg®) treatment in acute myeloid leukemia patients
VHJ van der Velden et al.
LEUKEMIA (2004)
Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia
F Lo-Coco et al.
BLOOD (2004)
A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia
WJ Kell et al.
BLOOD (2003)
Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+primary resistant or relapsed acute myeloid leukemia
A Tsimberidou et al.
LEUKEMIA RESEARCH (2003)
Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia
E Apostolidou et al.
LEUKEMIA RESEARCH (2003)
Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells
RB Walter et al.
BLOOD (2003)
Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate
R Ohno et al.
LEUKEMIA (2003)
Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3
D Amico et al.
BLOOD (2003)
Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes
A Tsimberidou et al.
CANCER (2003)
Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia
Y Alvarado et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2003)
Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia
J Cortes et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2002)
Differences in CD33 intensity between various myeloid neoplasms
I Jilani et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2002)
Siglecs: sialic-acid-binding immunoglobulin-like lectins in cell-cell interactions and signalling
PR Crocker
CURRENT OPINION IN STRUCTURAL BIOLOGY (2002)
Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)
RA Larson et al.
LEUKEMIA (2002)
New advances in the treatment of acute promyelocytic leukemia
D Douer
INTERNATIONAL JOURNAL OF HEMATOLOGY (2002)
Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside
EH Estey et al.
BLOOD (2002)
Experience with gemtuzumab ozogamycin (mylotarg), and all-trans retinoic acid in untreated acute promyelocytic leukemia
EH Estey et al.
BLOOD (2002)
Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers
H Matsui et al.
LEUKEMIA (2002)
Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia
PR Hamann et al.
BIOCONJUGATE CHEMISTRY (2002)
Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin
ML Linenberger et al.
BLOOD (2001)
Analysis of prognostic factors in newly diagnosed patients with acute promyelocytic leukemia: the APL92 study of the Japan Adult Leukemia Study Group (JALSG)
N Asou et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2001)
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse
EL Sievers et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells
VHJ van der Velden et al.
BLOOD (2001)
Repopulation of liver endothelium by bone-marrow-derived cells
ZH Gao et al.
LANCET (2001)
Share Paper
